title: Penile verrucous carcinoma successfully treated by intra-aortic infusion with methotrexate.
abstract: OBJECTIVE
  Penile verrucous carcinoma is characterized by aggressive local growth and a low metastatic potential. Lower abdominal aortic infusion chemotherapy has the main advantage of delivering a very high concentration of an anticancer drug to the whole pelvic area, including the penis, and is especially suitable to treat penile verrucous carcinoma.
  
  
  METHODS
  From 1991 to 2000, 4 cases of penile verrucous carcinoma were treated by continuous intra-aortic infusion with methotrexate (50 mg) every 24 hours, for an average of 10 days. Citrovorum factor (6 mg) was given intramuscularly every 6 hours during the period of methotrexate infusion.
  
  
  RESULTS
  After treatment, 3 patients achieved complete remission. They were living disease free 10 years, 10 months, 6 years, 9 months, and 1 year, 8 months after therapy.
  
  
  CONCLUSIONS
  Intra-aortic infusion chemotherapy is a simple and effective method for penile verrucous carcinoma with the unique advantage of preserving cosmetic and functional integrity. It may be considered an effective alternative treatment for penile verrucous carcinoma. By using this simple method many unnecessary penectomies can be avoided.
authors.affiliation: Department of Surgery, Division of Surgical Oncology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
authors.forename: Maw-Chang
authors.initials: MC
authors.lastname: Sheen
authors.forename: Hamm-Ming
authors.initials: HM
authors.lastname: Sheu
authors.forename: Chun-Hsiung
authors.initials: CH
authors.lastname: Huang
authors.forename: Yi-Wen
authors.initials: YW
authors.lastname: Wang
authors.forename: Chee-Yin
authors.initials: CY
authors.lastname: Chai
authors.forename: Chih-Fung
authors.initials: CF
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D001012:Aorta, Abdominal / Q000378:metabolism*; D018289:Carcinoma, Verrucous / Q000098:blood supply / Q000188:drug therapy*; D018572:Disease-Free Survival; D005076:Exanthema / Q000209:etiology; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010412:Penile Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D011537:Pruritus / Q000209:etiology; D012074:Remission Induction / Q000379:methods; D013624:Taiwan
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate